ESPERION THERAPEUTICS ($ESPR) posted quarterly earnings results on Tuesday, August 5th. The company reported earnings of -$0.02 per share, beating estimates of -$0.13 by $0.11. The company also reported revenue of $82,390,000, beating estimates of $65,045,542 by $17,344,458.
You can see Quiver Quantitative's $ESPR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ESPERION THERAPEUTICS Insider Trading Activity
ESPERION THERAPEUTICS insiders have traded $ESPR stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $ESPR stock by insiders over the last 6 months:
- SHELDON L. KOENIG (President and CEO) has made 0 purchases and 2 sales selling 43,521 shares for an estimated $53,418.
- BENJAMIN HALLADAY (Chief Financial Officer) has made 0 purchases and 5 sales selling 10,794 shares for an estimated $13,610.
- BENJAMIN LOOKER (General Counsel) has made 0 purchases and 2 sales selling 7,726 shares for an estimated $8,867.
- ERIC WARREN (Chief Commercial Officer) has made 0 purchases and 3 sales selling 2,780 shares for an estimated $4,169.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ESPERION THERAPEUTICS Hedge Fund Activity
We have seen 76 institutional investors add shares of ESPERION THERAPEUTICS stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WASATCH ADVISORS LP removed 13,551,001 shares (-55.4%) from their portfolio in Q1 2025, for an estimated $19,513,441
- MARSHALL WACE, LLP added 3,632,958 shares (+inf%) to their portfolio in Q1 2025, for an estimated $5,231,459
- PENDERFUND CAPITAL MANAGEMENT LTD. added 2,000,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,880,000
- CENTERBOOK PARTNERS LP removed 1,306,259 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,881,012
- GOLDMAN SACHS GROUP INC removed 1,225,974 shares (-44.5%) from their portfolio in Q1 2025, for an estimated $1,765,402
- WELLS FARGO & COMPANY/MN added 1,109,140 shares (+1023.2%) to their portfolio in Q1 2025, for an estimated $1,597,161
- TWO SIGMA ADVISERS, LP removed 1,089,200 shares (-30.1%) from their portfolio in Q1 2025, for an estimated $1,568,448
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ESPERION THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ESPR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/17/2025
- Needham issued a "Buy" rating on 05/07/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/05/2025
- JMP Securities issued a "Market Outperform" rating on 02/11/2025
To track analyst ratings and price targets for ESPERION THERAPEUTICS, check out Quiver Quantitative's $ESPR forecast page.
ESPERION THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ESPR recently. We have seen 5 analysts offer price targets for $ESPR in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $16.0 on 06/17/2025
- Serge Belanger from Needham set a target price of $4.0 on 05/07/2025
- Paul Choi from Goldman Sachs set a target price of $3.0 on 04/17/2025
- Jason Butler from Citizens Capital Markets set a target price of $4.0 on 03/05/2025
- Roy Buchanan from JMP Securities set a target price of $4.0 on 02/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
